特定于心肌细胞的C/EBPβ缺乏会加剧压力过重引起的心力衰竭
Jihoon Nah1,2, Eun-Ah Sung1, Peiyong Zhai1
1Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States.
Cardiovascular research
|January 31, 2026
概括
心脏细胞中的CCAAT增强剂结合蛋白β (C/EBPβ) 对于在压力过载时预防心力衰竭至关重要. 心肌细胞中C/EBPβ的损失会使心脏功能障碍和纤维化恶化,突出其保护作用.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 基因规则 基因规则
背景情况:
- CCAAT增强剂结合蛋白β (C/EBPβ) 是参与细胞过程的转录因子.
- 已知C/EBPβ在心脏中的作用,但其在心脏应激期间的细胞类型特异性功能尚不清楚.
研究的目的:
- 调查内源性C/EBPβ在压力过载引起的心力衰竭期间心肌细胞中的作用.
主要方法:
- 产生的心肌细胞特异性Cebpb淘汰 (Cebpb-cKO) 的小鼠.
- 对小鼠进行横向大动脉收缩 (TAC),以诱导压力过载.
- 评估心脏功能,缩,纤维化和基因表达.
主要成果:
- 在TAC后的野生型心脏中,C/EBPβ表达减少.
- 在TAC后,Cebpb-cKO小鼠表现出严重的缩功能障碍,高和纤维化.
- 失去C/EBPβ会减少抗氧化剂基因表达,并恶化心脏功能.
结论:
- 心肌细胞内源性C/EBPβ在压力过载时起着保护作用.
- C/EBPβ在心脏中表现出细胞类型特定的功能.
- 在心肌细胞中恢复C/EBPβ改善了TAC后的心脏功能.
相关概念视频
Heart Failure II: Pathophysiology
920
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
920
Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction
882
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
882
Heart Failure VI: Adjunct Therapies
336
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
336
Heart Failure Drugs: Diuretics
966
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
966
Heart Failure V: Medical Management
312
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
312


